IL4 and familial pancreatic carcinoma: Furthermore, the combination of inhibiting the IL-4/IL-13-receptor axis with chemotherapeutics, radiotherapy, and/or other small inhibiting molecules may provide attractive possibilities with high efficiency and specificity for pancreatic cancer treatment.